SPRY ARS Pharmaceuticals Inc

$SPRY This reminds me of the Titanic. Yet another new low. Why go down with the ship? Immense value with AQST. You'll thank me later.

$SPRY New management will be likely be seeking a near term win to prove they were the right choice/decision. They will still blame previous management for Q3 numbers if they are poor and will take credit for any positive forward guidance. Do I like the stock? No. I don't like the company and I hate it long term. But for a short term pop, I like it. Lot of eyes on it, sitting on the fence. Solid history of FOMO buying on news. It's primed for something to happen between now and November ER. Right after that is the ACAAI meeting. The biggest commercial event of the year for them. They will want to walk in there for the first time with a solid ER and news worthy victory to brag about. Then it will probably have a CVS formulary run in December. Volume is piss poor. Its oversold. Short availability is high. Borrow fees are so-so, in the 2's, but somewhat steady. My buy zone is anything sub $4.50. Won't touch it above that.

$SPRY 😂 The commercial bleed for SPRY Pharmaceuticals is much closer to exhaustion than it is for AQST. People told me I was crazy-and a degenerate-when I was in $ASTS with an average cost in the $3’s. They told me the same thing when I was in $PLTR at $16.50. If ARS Pharmaceuticals craters to $1 (which is highly unlikely), it doesn’t matter to me. I’ll sit on it for as long as it takes. Say what you will. I have a thesis, and I’m sticking to it. $SPRY is definitely out of favor. This asset is cheap in my opinion….undervalued with new leadership at the helm. New CEO and CCO with experience…both worked together at $MRK and Dynavax, acquired by $SNY • Already in 13,000+ U.S. schools • Gaining market share • Only needle-free epinephrine treatment currently on the market • Cash-flow breakeven targeted for 2027.

$SPRY $AQST Once it is completed, the rest of competitors in epi space are done, can close their shop and go home

$SPRY Lots of nasal spray competition coming neffy's way. Anaphylm™ Aquestive Therapeutics Sublingual film NDA received FDA Complete Response Letter Jan. 2026; Q3 2026 resubmission planned Hikma Hikma Pharmaceuticals Liquid nasal spray NDA accepted by FDA for review Sept. 2026 NS002 Nasus Pharma Dry-powder nasal Phase 2 completed; pivotal study planned Q4 2026 Nasdepi® Belhaven Biopharma Dry-powder nasal IND accepted; pivotal biocomparability study planned OX640 Orexo Dry-powder nasal Two clinical studies completed; advancing toward pivotal development; seeking partner IN-001 Insignis Therapeutics Sublingual liquid via prefilled oral syringe Phase 1 completed; Phase 2 in preparation ZENEO® Crossject Needle-free transcutaneous IM injection Clinical/device development ongoing; 2028 target timeframe

$SPRY cash flow to break even in 2027. #undervaluedasset #epinephrine #marketexpansion $MRK $SNY Great print. 7.34k TRX. 6% market share. Looks like early refills starting to kick in. NRX 5.7k. 5.3% market share.

$SPRY has NEW leadership with significant commercialization experience. CEO Donn Casale spent 14 years at $MRK later became CCO of Dynavax, helping drive HEPLISAV-B’s commercial growth. Dynavax was ultimately acquired by $SNY / Sanofi for approximately $ 2.2B. The story is simple. neffy is the first FDA and globally approved epinephrine nasal spray for severe allergic reactions-a needle-free alternative to traditional auto-injectors. It launched LESS THAN 2 years ago and is already in 13,000+ schools.

$SPRY Sleeper pipeline. Cutting cash-based SG&A by 40%+ while expanding the pipeline. CSU/chronic hives Phase 2b data expected Q1 2027 - a potential multibillion-dollar market. ARS-1 has also been studied in Phase 2 for persistent asthma versus albuterol. Cut costs. Expand indications. Add potential market value. $AXSM

$SPRY Just posting information. ARS did everything possible to block anaphylm from approval. Carry rates are an issue with epinephrine delivery. People lose their lives to anaphalaxis because they fail to carry to proper life saving device. Anaphylm can have a material impact on carry rates as a credit card sized pouch can easily fit on the back of a phone or in a wallet. This is a particular problems with young adults. In addition, time to Tmax is much faster with anaphylm. Despite the fact that lives could be saved, ARS still tried to block this from getting to patients. I do not wish ARS well. They only care about the bottom line (like most TBH). I hope Anaphylm is approved and eats their lunch. Biotech is cutthroat, and I hope Anaphylm wins. Non-device and faster time to tmax is a game changer. You know this. Understand this risk if you decide to hold SPRY long term. GL

$SPRY great print. 7.34k TRX. 6% market share. Looks like early refills starting to kick in. NRX 5.7k. 5.3% market share.

$SPRY hey big T ..you know SPRY and AQST short interest are virtually identical right? Only reason why you’re seeing 38 percent SI on SPRY is because the top 4 holders (some of the most prestigious healthcare funds in world) are long conviction holds and don’t day trade. They hold a ton of shares and bring the float to 63mil shares instead of 100mil… AQST 21 percent short outstanding shares Spry 23 percent SPRY massively bigger short squeeze potential due to the smaller float as stated above Food for thought buddy thought I’d educate you 😉

$SPRY Not a fan of SPRY, for multiple reasons, but mid $4's sub $4's, it does become attractive. Their one product didn't fail, former management failed the launch. Add to that, the obvious behind the scenes battle with Viatris has also slowed the launch. Before, after approval, the market gifted SPRY with a valuation that indicated a fast, successful launch. SPRY failed at that. Now, with new management, the market is now in 'prove it' mode. Giving SPRY a low valuation until they show they can launch Neffy they way it should. The market will want, likely, 2 quarters worth of time to see if new management can do the job, The CVS formulary approval, IF APPROVED, come January 2027, will be a big boost. This a good play to play, to run up into 3rdQ ER and the CVS formulary. The better play will always be AQST. But SPRY might have some bigger pops before AQST makes its 1X, 2X, 3X move. I wouldn't touch SPRY over $4.50. But under it, I would flip in and out of it for sure.

$SPRY fantastically looking chart. its down only 59%. let's see how much more damage can two new vaccine salesmen do in an allergy market. this is going to be fun to watch along with two other morons defending it.

$SPRY Market continues to reward fantastic execution and performance of this miracle drug.

$SPRY $AQST read the fine print: NO head-to-head comparison studies have been conducted with Anaphylm and Neffy. Aquestive Therapeutics, Inc. data results on file, excluding T-max data results for Neffy, which can be found in the prescribing information located in the approved product label

$SPRY $AQST peak absorption time matters. nasal spray may get you there in 30min if you don't leave it at home. ALso think about why many stayed with epipen. .... absorbtion time for sure has something to do with it.

$SPRY Stock price lingering at support line... If it drops to 4, support will have been broken

$SPRY TRX still around 5.5 percent as of Sep 11. Labor Day may have impacted but that’s market wide. CVS unlocking remains huge.

$SPRY Short interest continues to be sky high and increasing despite stock price near 52 week lows... Not a good outlook.

$SPRY Jeebus Crispy!! It can NOT be soon enough for the new CEO to turn this ship around... WTF is taking so long?